Cowen & Co Initiates Coverage on Luminex (LMNX) with a Neutral; Upside Potential, But Reflected In Premium Valuation
More News related to LMNX
- Luminex Corporation to Present at JPMorgan Healthcare Conference
- Luminex Corporation and Mingyuan Medicare Development Company Sign Distribution Agreement
- Luminex Corporation Announces First Commercial Shipment of FLEXMAP 3D Systems
- Unusual 11 Mid-Day Movers 11/07: LFG, FSYS, AN, KNOT Higher; GNW, DPTR, EGOV, SRZ Lower
- Luminex Corp (LMNX) Tops Q3 View By 7c
More News related to New Coverage
- Sterne Agee Downgrades World Acceptance Corp. (WRLD) to Neutral
- B. Riley Downgrades Trustmark (TRMK) to Sell
- B. Riley Downgrades Big 5 Sporting Goods (BGFV) to Neutral
- Sterne Agee Downgrades Suntrust Bank (STI) to Neutral
- Lazard Downgrades Allergan (AGN) to Hold
Cowen & Co initiates coverage on Luminex (Nasdaq: LMNX) with a Neutral.
Cowen analyst says, "Over the past several quarters, the company has sustained momentum which has helped drive shares to appreciate almost 20% YTD. While we are quite enthused about Luminex's growth prospects and potential for material operating leverage, our valuation analyses suggest that much of this potential is already reflected in the current valuation."
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the life sciences industry.
Related Categories
New CoverageStocks Mentioned
-0.25Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
